Investors
A functioning diagnostic asset
with a focused international strategy
Fidelion combines a functioning tumour-naive MRD workflow and operating experience with an international programme spanning validation, access and longitudinal data.
The Fidelion thesis
Start with what works
then build around time
VitaGuard has commercial operating experience and a tumour-naive approach designed to begin from blood without first developing a patient-specific assay from tumour tissue.
Fidelion holds assigned international development and commercialisation rights outside Greater China. The opportunity is to transfer the workflow, validate defined uses and build laboratory access—then grow governed longitudinal intelligence from reliable repeat testing.
Execution through milestones
Turn strategy
into measurable progress
Fidelion’s value-creation plan is designed to convert scientific and operating uncertainty into auditable progress.
Transfer workflow
Prove performance
Validate CRC use
Build quality systems
Access through partner labs
How the platform could develop
The test creates the foundation
Time expands the opportunity
VitaGuard MRD
A functioning laboratory-developed testing workflow with commercial operating experience.
Validation and access
Earn confidence in defined uses and work with partners to establish responsible routes into new markets.
Software and data
Create governed molecular timelines and clearer ways to understand change across repeat results.
AI-assisted oncology
Research and validate potential applications in recurrence, response and resistance.
Financial information
Financial and reporting materials as Fidelion’s disclosure programme develops.
Explore →02Corporate governance
The principles intended to guide oversight, accountability and durable growth.
Explore →03Capital strategy
How operating progress can preserve long-term capital options.
Explore →04Corporate information
Contact Fidelion with questions about the company, its strategy and development.
Contact →Why Fidelion
A functioning diagnostic asset opens
a larger longitudinal opportunity
A functioning workflow
Tumour-naive MRD with an established operating history.
An international platform
Assigned development, manufacturing and sublicensing rights outside Greater China, subject to governing arrangements.
A focused first wedge
Colorectal cancer validation and delivery through qualified laboratory partners.
Longitudinal intelligence
Future software, governed oncology data and carefully validated analytical applications.
Fidelion is privately held. Nothing on this website constitutes an offer to sell or a solicitation to buy securities, and no securities offering or public listing is being presented here. This information is not investment advice. Statements about future products, data capabilities or AI-assisted applications describe development ambitions and remain subject to validation, regulation, data rights, financing and execution.